Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Can J Infect Dis Med Microbiol. 2005 Jul;16(4):233-43.

HIV-associated lipodystrophy syndrome: A review of clinical aspects.

Author information

  • 1Members of Le Comité consultatif sur la prise en charge Clinique des personnes vivant avec le VIH/Sida MinistAre de la Santé et des services sociaux du Québec.

Abstract

Approximately two years after the introduction of highly active antiretroviral therapy for the treatment of HIV infection, body shape changes and metabolic abnormalities were increasingly observed. Initially, these were ascribed to protease inhibitors, but it is now clear that nucleoside reverse transcriptase inhibitors also contribute to lipodystrophy syndrome. The syndrome groups together clinical conditions describing changes in body fat distribution that include lipoatrophy, lipoaccumulation or both. However, there does not appear to be a direct link between lipoatrophy and lipoaccumulation that would support a single mechanism for the redistribution of body fat. Currently, there is no clear definition of lipodystrophy, which explains the difficulty in determining its prevalence and etiology. There are no current guidelines for the treatment of fat distribution abnormalities that occur in the absence of other metabolic complications. The present article reviews the current state of knowledge of the definition, symptoms, risk factors, pathogenesis, diagnosis and treatment of the morphological changes associated with lipodystrophy syndrome.

KEYWORDS:

Adverse events; Antiretroviral drugs; Fat accumulation; HIV infection; Lipoatrophy; Lipodystrophy; Metabolic complications

PMID:
18159551
[PubMed]
PMCID:
PMC2095035
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk